Gould, Todd D.

The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions

Gottesman, I. I., & Gould, T. D. (2003) · American Journal of Psychiatry

Genetic Associations and EpidemiologyMental Health and Psychiatry

Cited by 5,615

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,609

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,260

Mechanisms of ketamine action as an antidepressant

Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,127

Toward constructing an endophenotype strategy for bipolar disorders

Hasler, G., Drevets, W. C., Gould, T. D., Gottesman, I. I., & Manji, H. K. (2006) · Biological Psychiatry

Bipolar Disorder and TreatmentSchizophrenia research and treatment

Cited by 423

CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease

Bhat, S., Dao, D. T., Terrillion, C. E., Arad, M., Smith, R. J., Soldatov, N. M., & Gould, T. D. (2012) · Progress in Neurobiology

Bipolar Disorder and TreatmentSchizophrenia research and treatment

Cited by 271

Endophenotypes in bipolar disorder

Lenox, R. H., Gould, T. D., & Manji, H. K. (2002) · American Journal of Medical Genetics

Bipolar Disorder and TreatmentSchizophrenia research and treatment

Cited by 264

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects

Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A. (2019) · Molecular Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 250

Mechanisms of ketamine and its metabolites as antidepressants

Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 175

Convergent Mechanisms Underlying Rapid Antidepressant Action

Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 171

Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function

Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 158

( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions

Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 152

The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics

O’Donnell, K. C., & Gould, T. D. (2007) · Neuroscience & Biobehavioral Reviews

Bipolar Disorder and TreatmentTreatment of Major Depression

Cited by 137

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants

Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 133

NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine

Zanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 115

Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters

Can, A., Zanos, P., Moaddel, R., Kang, H. J., Dossou, K. S. S., Wainer, I. W., Cheer, J. F., Frost, D. O., Huang, X.-P., & Gould, T. D. (2016) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 115

A negative allosteric modulator for α5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice

Zanos, P., Nelson, M. E., Highland, J. N., Krimmel, S. R., Georgiou, P., Gould, T. D., & Thompson, S. M. (2017) · eNeuro

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 106

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications

Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 92

Ketamine and the Future of Rapid-Acting Antidepressants

Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 87

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression

Farmer, C. A., Gilbert, J. R., Moaddel, R., George, J., Adeojo, L., Lovett, J., Nugent, A. C., Kadriu, B., Yuan, P., Gould, T. D., et al. (2020) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 85

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites

Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 83

(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses

Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 82

Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis

Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 75

(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism

Riggs, L. M., Aracava, Y., Zanos, P., Fischell, J., Albuquerque, E. X., Pereira, E. F. R., Thompson, S. M., & Gould, T. D. (2020) · Neuropsychopharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 66